Abstract: . . .  (ESRD). Lancet 2001;358:2113-17. 3. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004;24:1023-30. 4. Cooke JP. Asymmetrical dimethylarginine: the ber marker? Circulation 2004;109:1813-18. 5. All about ADMA. w ww.allaboutadma.com (l ast accessed on December 08, 2004). 6. Schulze F, Wesemann R, Schwedhelm E, et al. Determination of ADMA using a novel . . .
. . .  2001;358:2113-17. 3. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004;24:1023-30. 4. Cooke JP. Asymmetrical dimethylarginine: the ber marker? Circulation 2004;109:1813-18. 5. All about ADMA. w ww.allaboutadma.com (l ast accessed on December 08, 2004). 6. Schulze F, Wesemann R, Schwedhelm E, et al. Determination of ADMA using a novel ELISA  . . .
. . .  health and disease . References 1. Bger RH. The emerging role of ADMA as a novel cardiovascular risk factor. Cardiovasc Res 2003;59:824-33. 2. Zoccali C, Bode-Bger SM, Mallamaci F, et al. Asymmetric dimethylarginine (ADMA): An endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD). Lancet 2001;358:2113-17. 3. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine . . .
. . .  and other diseases . The observation made in the late 1990s that ADMA levels increased early during the development of atherosclerosis Page 2 suggested that ADMA had the potential to be not only a marker, but a mediator of vascular lesions. Data has recently accumulated from a series of clinical studies which confirm the potential role of ADMA as a marker of cardiovascular risk. High ADMA levels were found to be associated with carotid artery . . .
. . .  assessed in prospective clinical studies. Page 5 Figure Legends Figure 1. Schematic representation of the pathophysiological sequelae of elevated ADMA levels, which result from its ability to inhibit endothelial NO formation. Figure 2. Relationship between the determination of ADMA in human serum by the novel ADMA- ELISA and by liquid chromatography mass spectrometry. ADMA reduced vasodilatation Platelet . . .
--2565,5,256,2957,12823